Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
Identifieur interne : 004A76 ( PubMed/Checkpoint ); précédent : 004A75; suivant : 004A77Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
Auteurs : J J Van Hilten [Pays-Bas] ; A D Van Der Zwan ; A H Zwinderman ; R A RoosSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Activities of Daily Living (classification), Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Disability Evaluation, Female, Humans, Male, Middle Aged, Neurologic Examination (classification), Neurologic Examination (drug effects), Neurologic Examination (statistics & numerical data), Parkinson Disease (classification), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Reproducibility of Results.
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- classification : Activities of Daily Living, Neurologic Examination, Parkinson Disease.
- diagnosis : Parkinson Disease.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- statistics & numerical data : Neurologic Examination.
- chemical , therapeutic use : Antiparkinson Agents.
- Adult, Aged, Aged, 80 and over, Disability Evaluation, Female, Humans, Male, Middle Aged, Reproducibility of Results.
Abstract
Although the Unified Parkinson's Disease Rating Scale (UPDRS) is widely used to monitor disease progression and drug efficacy, no attempts have been made to evaluate its scientific and clinical quality. Poor clinical sensibility of items in the activities of daily living (ADL) section and redundancy of items in the motor examination (ME) section prompted us to determine if the number of items in these sections could be reduced to a smaller, equally sensitive set that would describe the data as reliably as did the original set of items. Therefore, we assessed 111 patients with idiopathic Parkinson's disease on the UPDRS and Hoehn and Yahr staging scales. Our results show that the ADL (13 items) and ME (14 items) sections can be reduced to 8 items each without loss of reliability or validity. Our report is preliminary and needs validation.
DOI: 10.1002/mds.870090113
PubMed: 8139609
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:8139609Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.</title><author><name sortKey="Van Hilten, J J" sort="Van Hilten, J J" uniqKey="Van Hilten J" first="J J" last="Van Hilten">J J Van Hilten</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Academic Hospital, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Academic Hospital, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Van Der Zwan, A D" sort="Van Der Zwan, A D" uniqKey="Van Der Zwan A" first="A D" last="Van Der Zwan">A D Van Der Zwan</name></author><author><name sortKey="Zwinderman, A H" sort="Zwinderman, A H" uniqKey="Zwinderman A" first="A H" last="Zwinderman">A H Zwinderman</name></author><author><name sortKey="Roos, R A" sort="Roos, R A" uniqKey="Roos R" first="R A" last="Roos">R A Roos</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:8139609</idno><idno type="pmid">8139609</idno><idno type="doi">10.1002/mds.870090113</idno><idno type="wicri:Area/PubMed/Corpus">004B49</idno><idno type="wicri:Area/PubMed/Curation">004B49</idno><idno type="wicri:Area/PubMed/Checkpoint">004A76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.</title><author><name sortKey="Van Hilten, J J" sort="Van Hilten, J J" uniqKey="Van Hilten J" first="J J" last="Van Hilten">J J Van Hilten</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Academic Hospital, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, Academic Hospital, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Van Der Zwan, A D" sort="Van Der Zwan, A D" uniqKey="Van Der Zwan A" first="A D" last="Van Der Zwan">A D Van Der Zwan</name></author><author><name sortKey="Zwinderman, A H" sort="Zwinderman, A H" uniqKey="Zwinderman A" first="A H" last="Zwinderman">A H Zwinderman</name></author><author><name sortKey="Roos, R A" sort="Roos, R A" uniqKey="Roos R" first="R A" last="Roos">R A Roos</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living (classification)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Disability Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (classification)</term><term>Neurologic Examination (drug effects)</term><term>Neurologic Examination (statistics & numerical data)</term><term>Parkinson Disease (classification)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Reproducibility of Results</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term><term>Neurologic Examination</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disability Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Reproducibility of Results</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the Unified Parkinson's Disease Rating Scale (UPDRS) is widely used to monitor disease progression and drug efficacy, no attempts have been made to evaluate its scientific and clinical quality. Poor clinical sensibility of items in the activities of daily living (ADL) section and redundancy of items in the motor examination (ME) section prompted us to determine if the number of items in these sections could be reduced to a smaller, equally sensitive set that would describe the data as reliably as did the original set of items. Therefore, we assessed 111 patients with idiopathic Parkinson's disease on the UPDRS and Hoehn and Yahr staging scales. Our results show that the ADL (13 items) and ME (14 items) sections can be reduced to 8 items each without loss of reliability or validity. Our report is preliminary and needs validation.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8139609</PMID><DateCreated><Year>1994</Year><Month>04</Month><Day>25</Day></DateCreated><DateCompleted><Year>1994</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>1994</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.</ArticleTitle><Pagination><MedlinePgn>84-8</MedlinePgn></Pagination><Abstract><AbstractText>Although the Unified Parkinson's Disease Rating Scale (UPDRS) is widely used to monitor disease progression and drug efficacy, no attempts have been made to evaluate its scientific and clinical quality. Poor clinical sensibility of items in the activities of daily living (ADL) section and redundancy of items in the motor examination (ME) section prompted us to determine if the number of items in these sections could be reduced to a smaller, equally sensitive set that would describe the data as reliably as did the original set of items. Therefore, we assessed 111 patients with idiopathic Parkinson's disease on the UPDRS and Hoehn and Yahr staging scales. Our results show that the ADL (13 items) and ME (14 items) sections can be reduced to 8 items each without loss of reliability or validity. Our report is preliminary and needs validation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Hilten</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Hospital, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Zwan</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Zwinderman</LastName><ForeName>A H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Roos</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000203">Activities of Daily Living</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D004185">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000706">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8139609</ArticleId><ArticleId IdType="doi">10.1002/mds.870090113</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Méridionale</li></region><settlement><li>Leyde</li></settlement></list><tree><noCountry><name sortKey="Roos, R A" sort="Roos, R A" uniqKey="Roos R" first="R A" last="Roos">R A Roos</name><name sortKey="Van Der Zwan, A D" sort="Van Der Zwan, A D" uniqKey="Van Der Zwan A" first="A D" last="Van Der Zwan">A D Van Der Zwan</name><name sortKey="Zwinderman, A H" sort="Zwinderman, A H" uniqKey="Zwinderman A" first="A H" last="Zwinderman">A H Zwinderman</name></noCountry><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Van Hilten, J J" sort="Van Hilten, J J" uniqKey="Van Hilten J" first="J J" last="Van Hilten">J J Van Hilten</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004A76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:8139609
|texte= Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:8139609" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |